| ESMO Open | |
| Prognostic role of distant disease-free interval from completion of adjuvant trastuzumab in HER2-positive early breast cancer: analysis from the ALTTO (BIG 2-06) trial | |
| article | |
| Matteo Lambertini1  Dominique Agbor-Tarh3  Otto Metzger-Filho4  Noam F. Ponde5  Francesca Poggio6  Florentine S. Hilbers7  Larissa A. Korde8  Saranya Chumsri9  Olena Werner1,10  Lucia Del Mastro1  Rafael Caparica1,11  Volker Moebus1,12  Alvaro Moreno-Aspitia9  Martine J. Piccart1,11  Evandro de Azambuja1,11  | |
| [1] Department of Internal Medicine and Medical Specialties ,(DiMI), School of Medicine, University of Genova;Department of Medical Oncology, U.O.C Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino;Frontier Science Scotland;Department of Medicine, Dana-Farber Cancer Institute, Harvard Medical School;Breast Cancer Unit, AC Camargo Cancer Center;Breast Unit, IRCCS Ospedale Policlinico San Martino;Breast International Group;Clinical Investigations Branch, National Cancer Institute;Oncology Department, Mayo Clinic;Novartis International AG;Medical Oncology Department, Institut Jules Bordet and l"Université Libre de Bruxelles;Medical Clinic II, Department of Hematology/Oncology, University Hospital Frankfurt | |
| 关键词: breast cancer; HER2-positive; adjuvant therapy; trastuzumab; prognosis; | |
| DOI : 10.1136/esmoopen-2020-000979 | |
| 学科分类:社会科学、人文和艺术(综合) | |
| 来源: BMJ Publishing Group | |
PDF
|
|
【 摘 要 】
Background In HER2-positive breast cancer, time elapsed between completion of (neo)adjuvant trastuzumab and diagnosis of metastatic disease (‘trastuzumab-free interval’, TFI) is crucial to choose the optimal first-line treatment. Nevertheless, there is no clear evidence to support its possible prognostic role.Methods In the Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation (ALTTO) trial, patients with HER2-positive early breast cancer were randomised to 1 year of either trastuzumab alone, lapatinib alone, their sequence or their combination. This exploratory analysis included only patients in the trastuzumab alone or trastuzumab plus lapatinib arms who developed a distant disease-free survival (DDFS) event. Overall survival (OS) was defined as time between date of DDFS event and death; age at diagnosis, tumour size and hormone receptor status were the variables included in the multivariate models.Results Out of 8381 patients included in ALTTO, 404 patients in the trastuzumab alone and trastuzumab plus lapatinib arms developed a DDFS event, of which 201 occurred <12 months (group B) after completion of adjuvant trastuzumab. No significant difference in location of first DDFS event was observed (p=0.073); a numerically higher number of patients in group A than in group B developed brain metastasis (26% vs 15%). Choice of first-line therapy differed between the two groups (p=0.022): in group A, more patients received lapatinib (25% vs 11%) and less pertuzumab (8% vs 17%). Median OS was 29.3 and 18.4 months in groups B and A, respectively (adjusted HR 0.69; 95% CI 0.54–0.89; p=0.004). The longer OS for patients in group B was observed across the analysed subgroups without interaction according to hormone receptor status (p=0.814) nor type of administered adjuvant anti-HER2 treatment (p=0.233).Conclusions TFI has prognostic value in patients with HER2-positive early breast cancer treated with adjuvant trastuzumab-based therapy. TFI is a valid tool to better individualise clinical recommendations and to design future first-line treatment trials for metastatic patients.
【 授权许可】
CC BY|CC BY-NC-ND
【 预 览 】
| Files | Size | Format | View |
|---|---|---|---|
| RO202303290004792ZK.pdf | 1517KB |
PDF